An observational study in Chronic Non-Cancer Pain and Opioid Use Disorder, sponsored by Uppsala University. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.
Sponsored by Uppsala University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Opioid-Related Disorders with a site in Sweden — 2 open to participants now, 4 under way, none of them phase 3. Opioid-Related Disorders · Sweden.
Among the 13 studies in Opioid-Related Disorders with a site in Sweden, this one is the only one that started in 2019, is one of 7 observational ones, and was the 11th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →2 of the 13 studies in Opioid-Related Disorders with a site in Sweden are open now. Recruiting first, the newest first:
Uppsala University · Sites in Sweden
Ages 18–75
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 129 across 184 observational studies indexed under Opioid-Related Disorders.
Median enrollment 80 across the 6 interventional studies, 480 across the 7 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 9 most frequent:
Uppsala University is the lead sponsor of 390 studies on the registry; 86 are open to participants now.
Uppsala University has 3 studies filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies in Opioid-Related Disorders with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063902Uppsala UniversityLong-Term Opioid Therapy in Chronic Non-Cancer Pain: Risks and Benefits | 2027-01-14 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Opioid-Related Disorders with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study investigates long-term opioid treatment in patients with chronic non-cancer pain (CNCP). The study aims to prospectively identify predictive factors for work ability and for developing opioid use disorder (according to DSM-5) as well as predictive factors for pain, activity, and health-related quality of life.
It is hypothesized that certain biopsychosocial factors mapped in this study predict patterns of opioid use and the risk for developing OUD for patients with CNCP on long-term opioid therapy. Further, it is hypothesized that certain biopsychosocial factors mapped in this study predict the chance of improved work ability and other treatment benefits of long term opioid therapy in patients with CNCP.
Chronic pain affects nearly 20% of the Swedish population. Pain from the musculoskeletal system together with psychiatric disorders are the chronic conditions that cost the most for the Swedish health care disability insurance and health care systems. Current knowledge suggests that chronic pain is maintained by changes in the nervous system together with psychological and social factors.
Opioids are known to be effective for acute and post-operative pain, and can be indispensable in palliative treatment of cancer pain. Long-term opioid therapy on the other hand is associated witg several risks, e.g., development of opioid dependence and opioid use disorder (OUD), and other opioid related complications including premature death. Clinical experience, qualitative and quantitative research suggest that some individuals with chronic pain do benefit from long-term opioid therapy in terms of clinical significant pain relief with only a low level of negative side-effects. However, evidence of change in functional outcomes and health related quality of life is ambiguous. Therefore, the role of long-term opioid therapy in chronic pain conditions remains debated and sometimes controversial.
In contrast to the well-established opioid epidemic in the U.S., little is known about the use of prescribed opioids in Sweden, and how this has developed during the last decade. The annual prevalence of opioid prescription did not change much during 2006-2017, but there were significant shifts in choice of opioids, with an increase in strong opioids e.g., oxycodone and morphine. Very little is known about what clinical consequences this shift might lead to.
The U-PAIN cohort study aims to examine patterns of prescribed opioid use, risks of adverse effects of long-term opioid therapy, and benefits of long-term opioid therapy, in a prospective clinical cohort.
The study aims to complete a broad bio-psycho-social characterization of the participants relevant to chronic pain. The study participants are followed over 5 years in order to study trajectories for patterns of opioid use, and predictive factors for opioid use disorder, work ability, pain severity and interference, and health-related quality of life.
At baseline, participants will be classified into 4 groups based on their current use of opioids:
Main research questions for the cohort study are:
What variables predict their future:
Potential predictors and co-variates include: (1) Individual factor and demographic variables (2) Pain characteristics, (3) Psychiatric co-morbidity and susceptibility for OUD, (3) Cognitive-behavioral variables, and (4) Physical functioning.
The objective is to identify the most salient predictors from each group and combine them into a final model with the best goodness of fit.
The four groups concerning patterns of opioid use will be statistically compared regarding key outcomes at baseline (opioid use disorders, work ability, activity interference, pain and HQoL)) by use of t-tests and chi-square tests. Logistic regression analyses will be applied for the study of predictors of opioid use, OUD, work ability, activity interference and pain. The dependent variables, e.g. OUD/no OUD will be regressed towards hypothetic predictors, grouped as described earlier, to end up with a final model including the most salient predictors from each group of variables. Multivariate regression models will be considered for continuous dependent variables.
In addition this clinical cohort will be open for other studies after ethical vetting, i.e. the cohort is unique and could contribute to further understanding of this population and hence should be open for further research.
Patients with moderate to severe CNCP referred to secondary and tertiary pain care at the Uppsala University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Characterization and changes in opioid use disorder
As defined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Measured by: Structured interview: Modified version of the Swedish Mini International Neuropsychiatric Interview, Part J (Substance use). Response format yes/no. Mild opioid use disorder = 2-3 symptoms Moderate opioid use disorder = 4-5 symptoms Severe opioid use disorder = 6 or more symptoms
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Changes in work ability
Self report. Work Ability Index (WAI). The questionnaire covers 7 dimensions: 1. current work ability compared with lifetime best 2. work ability in relation to the demands of the job 3. number of diagnosed illnesses or limiting conditions 4. estimated impairment owing to diseases/illnesses or limiting conditions 5. amount of sick leave during the last year 6. prognosis of work ability in 2 years' time 7. psychological resources. The dimensions have different scores. A total index is computed ranging from 7 to 49, where higher scores indicate higher work ability. Individual items or sub-scales of WAI may also be used as outcome measures.
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Changes and patterns of opioid use (type of opioid, dose, and duration)
The Time Line Follow-Back (TLFB) Structured interview, calendar format, using 4 week intervals starting with the most recent complete week, week 1, working backward one week at a time recording days of use for each opioid.
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Changes in pain severity and pain interference: The Brief Pain Inventory short-form (BPI-SF)
Self report. The Brief Pain Inventory. Pain severity is measured with 4 items where worst, least, average, and current pain during the past week are scored. Each scale ranges from 0-10, where 0 = 'no pain' and 10 = 'pain as bad as can be'. Pain interference is measured with 7 items measuring how pain have interfered with the respondent's general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life during the last 24 ours. Each scale ranges from 0-10, where 0 = 'Does not interfere' and 10 = 'Interferes completely'. Higher scores indicate more pain severity and pain interference.
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Changes in health related quality of life: EQ-5D-5L
Self report. The EuroQoL - Five dimension (EQ-5D-5L). The five dimensions are: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with five levels of functioning: "1=no problems," "2=slight problems," "3=moderate problems," "4=severe problems," and "5=unable to"/ "extreme problems" for all dimensions that describe unique health states.The health states can be converted into index scores derived from population-based studies, that ranges from states worse than dead (\<0) to 1 (full health), anchoring dead at 0.The EQ-5D questionnaire also includes a visual analog scale where perceived health status is rated with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Depressive symptoms
Self report: Patient Health Questionnaire - 9 (PHQ-9), Swedish version. 9 items ranging from 0 ='not at all', to 3 ='almost every day'. 1 item ranging from 0 ='no difficulties, to 3 = 'extreme difficulties'. The first 9 items are summed to a sum score ranging from 0 to 27, where: 0-4 = no signs of depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, 20-27 = severe depression. Item 10 is reported as a single item where high scores indicate high interference with daily function.
Time frame: Baseline
Generalised Anxiety Disorder
Self report: Generalised Anxiety Disorder (GAD-7). 7 items ranging from 0 ='not at all', to 3 ='almost every day'. 1 item ranging from 0 ='no difficulties, to 3 = 'extreme difficulties'. 1 item ranging from 0 ='not at all, to 3 = 'very disturbing'. The first 7 items are summed to a sum score ranging from 0 to 21, where: 0-4 = no signs of anxiety, 5-9 = mild GAD, 10-14 = moderate GAD, 15-21 = severe GAD. Item 8 is reported as a single item where higher score means higher interference.
Time frame: Baseline
Sleep
Self-report: The insomnia severity index (ISI) The ISI comprises 7 items that assess current (i.e., preceding 2 weeks) sleep problems. The first three items evaluate the severity of sleep onset, sleep maintenance, and early morning awakening problems. Subsequent items assess current sleep problem, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and amount of worry due to the current sleep problem. Items are rated on a five-point Likert scale ('0' representing none or not at all and '4' representing very much). Total scores range from 0 to 28, with higher combined scores indicating worse insomnia severity.
Time frame: Baseline
Pain self-efficacy
The Pain Self-Efficacy Questionnaire 2 (PSEQ-2), comprises 2 items that asses the participants beliefs about their ability to accomplish activities despite their pain: 'I can do some form of work, despite the pain. ("work" includes housework,paid and unpaid work)', and 'I can live a normal lifestyle, despite the pain'. Items are rated on a seven-point Likert scale ('0' not confident at all '6' Completelt confident). Total scores range from 0 to 12, with higher combined scores indicating stronger self-efficacy beliefs.
Time frame: Baseline
Experienced injustice
Self report: Injustice Experience Questionnaire (IEQ), Swedish version. IEQ measure the degree of experienced injustice following an injury. Respondents are asked to indicate on a five-point scale, ranging from 0 ='never, to 4 ='all the time'. The total score is calculated by adding the scores of each item. A total score is computed by summing the scores to all 12 items, ranging from 0-48 where higher scores indicate higher experience of injustice.
Time frame: Baseline
Fear of movement and reinjury
Self report, The Tampa Scale of Kinesiophobia-11 (TSK-11), Swedish version. 11 items ranging from 1 to 4 where 1 = 'does not agree at all', 4 = 'totally agree'. A total score is calculated ranging from 11 to 44 where higher scores indicate higher fear of movement/kinesiophobia.
Time frame: Baseline
Catastrophizing - The Pain Catastrophizing Scale (PCS) - Swedish version.
Self report, self-administered form. The Pain Catastrophizing Scale (PCS) - Swedish version. 13 items, ranging from 0 to 4 where 0 = 'not at all', 4 = 'all the time'. A total score is calculated ranging from 0 to 52 where higher scores indicate higher catastrophizing.
Time frame: Baseline
Changes in life habits
Self-report. The Lifestyle questionnaire by the Swedish National Board of Health. Assesses physical activity and sedentary (duration in minutes and intensity), tobacco use (any use, tobacco cessation= stopped using\> 6 month ago or stopped\< than 6 months, and amount), diet (eating vegetables, fruit/berries, fish or shellfish, and candy/cookies; twice/day, once/day, couple of times/week, once/week, couple of times/month or less. Breakfast; every day, almost every day, few days/week, one/week or less) and alcohol use (any use, occasions/week and amount).
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Alcohol Use
Self report: Alcohol Use Disorder Identification Test (AUDIT) Swedish version, a 10-item measure of past-year harmful and hazardous alcohol use. The AUDIT addresses three conceptual domains: alcohol consumption (three items), alcohol-related problems (four items), and adverse psychological reactions (three items). The first 8 items are scored on a 5-point scale ranging from 0 to 4, and the last two are scored on a 3-point scale with values 0, 2, and 4. The total score ranges from 0-40 with cut-off values of 8 and 6 points for men and women respectively indicate hazardous alcohol use and a score of ≥19, indicates alcohol-related problems including dependence.
Time frame: Baseline
Illicit drug use
Self report. The Drug Use Disorder Identification test (DUDIT) Swedish version,an 11-item screening instrument developed to identify non-alcohol drug use patterns and drug-related problems. The first nine items are scored on a 5-point scale ranging from 0 to 4, and the last two are scored on a 3-point scale with values 0, 2, and 4. Thus, scores range from 0-44 with higher scores indicating a more severe drug problem, with cut-off values of 4 and 2 points for men and women respectively indicate hazardous drug use.
Time frame: Baseline
Pain classification
International classification of disease (ICD-11).
Time frame: Baseline
Personality traits
Self report. Swedish universities scale of personality (SSP), an instrument developed to measure personality traits intended to be markers for various neurobiological processes related to vulnerability to mental illness. It consists of 91 items that generates 13 different scales. For all items the respondent fill in one of four possible answer alter; not true at all, does not match particularly well, agree somewhat, exactly right. Each of the 13 scales represent relevant personality aspects and are as follow; Somatic trait anxiety (STA), Psychic trait anxiety (PsTA), Stress susceptibility (SS), Lack of assertiveness (LA), Detachment (D), Embitterment (E), Mistrust (M), Physical trait aggression (PhTA), Verbal trait aggression (VTA), Adventure seeking (AS), Impulsiveness (I), Social desirability (SD), and Trait irritability (TI). SSP has also been factor-analysed into three major dimensions, Neuroticism, Aggressiveness and Extraversion.
Time frame: Baseline
Attention-deficit hyperactivity disorder (ADHD) symptoms
Self report. ADHD Self-Report Scale (ASRS v.1.1) includes 18 items of recent DSM-IV Criterion A symptoms of adult ADHD. Respondents are asked how often a symptom has occurred over the past 6 months on a scale ranging from 0 to 4 (never, rarely, sometimes, often and very often).
Time frame: Baseline
Life-time experience of traumatic events
Self-report. the Life Events Checklist (LEC) consists of 16 items inquiring about the experience of 16 different potentially traumatic events (PTE) known to result in PTSD or other posttraumatic difficulties. For each PTE, respondents rate their experience of that event on a 5-point nominal scale (1 = happened to me, 2 = witnessed it, 3 = learned about it, 4 = not sure, and 5 = does not apply).
Time frame: Baseline
Walk speed
Physical functional test. 10 meters test of walking
Time frame: Baseline
Balance
Physical functional test.The Mini Balance Evaluation Systems Test (mini-BESTest) consist of 14 item measuring dynamic balance. Each item is scored on a 3-category ordinal scale from 0 (unable or requiring help to perform) to 2 (normal) with a total score from 0 to 28.
Time frame: Baseline
Substance use and substance use disorder
Structured interview: Modified version of the Swedish Mini International Neuropsychiatric Interview, Part J (Substance use). The M.I.N.I (J) assesses eight categories of substances, including both prescribed medications and illicit substances: opioids (heroin and opium as a separate category), stimulants, cocaine, hallucinogens, inhalants, marijuana, and benzodiazepines. The substance use disorder section was modified to assess current as well as life-time drug use, and medical as well as non-medical use. Response format yes/no. Substance use disorder defined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Mild substance use disorder = 2-3 symptoms Moderate substance use disorder= 4-5 symptoms Severe substance use disorder = 6 or more symptoms
Time frame: Baseline
Explorative identification of change in biomarkers
Biomarkers will be explored by use of the OLINK (name of brand) panel which enables analysis of 92 inflammation-related protein biomarkers.
Time frame: Baseline
Experienced effect of treatment/Global goal achievement
Self report. Patient global impression of change (PGIC). The measure reflects participant's beliefs about the efficacy of treatment. The patient rates overall improvement on a 7-point scale where 3 = 'very much improved', 2 = 'much improved', 1 = 'minimally improved', 0 = 'no change', -1 = 'minimally worse', -2 = 'much worse', and -3 ='very much worse'.
Time frame: 1 year
Experienced effect of treatment/Global goal achievement
Self report. Patient global impression of change (PGIC). The measure reflects participant's beliefs about the efficacy of treatment. The patient rates overall improvement on a 7-point scale where 3 = 'very much improved', 2 = 'much improved', 1 = 'minimally improved', 0 = 'no change', -1 = 'minimally worse', -2 = 'much worse', and -3 ='very much worse'.
Time frame: 2 year
Experienced effect of treatment/Global goal achievement
Self report. Patient global impression of change (PGIC). The measure reflects participant's beliefs about the efficacy of treatment. The patient rates overall improvement on a 7-point scale where 3 = 'very much improved', 2 = 'much improved', 1 = 'minimally improved', 0 = 'no change', -1 = 'minimally worse', -2 = 'much worse', and -3 ='very much worse'.
Time frame: 3 year
Experienced effect of treatment/Global goal achievement
Self report. Patient global impression of change (PGIC). The measure reflects participant's beliefs about the efficacy of treatment. The patient rates overall improvement on a 7-point scale where 3 = 'very much improved', 2 = 'much improved', 1 = 'minimally improved', 0 = 'no change', -1 = 'minimally worse', -2 = 'much worse', and -3 ='very much worse'.
Time frame: 4 year
Experienced effect of treatment/Global goal achievement
Self report. Patient global impression of change (PGIC). The measure reflects participant's beliefs about the efficacy of treatment. The patient rates overall improvement on a 7-point scale where 3 = 'very much improved', 2 = 'much improved', 1 = 'minimally improved', 0 = 'no change', -1 = 'minimally worse', -2 = 'much worse', and -3 ='very much worse'.
Time frame: 5 year
Sick-leave
Register data. Average sick leave according to the Swedish Social Insurance register, defined as net days.
Time frame: Baseline
Sick-leave
Register data. Average sick leave according to the Swedish Social Insurance register, defined as net days.
Time frame: 1 year
Sick-leave
Register data. Average sick leave according to the Swedish Social Insurance register, defined as net days.
Time frame: 2 year
Sick-leave
Register data. Average sick leave according to the Swedish Social Insurance register, defined as net days.
Time frame: 3 year
Sick-leave
Register data. Average sick leave according to the Swedish Social Insurance register, defined as net days.
Time frame: 4 year
Sick-leave
Register data. Average sick leave according to the Swedish Social Insurance register, defined as net days.
Time frame: 5 year
Prescribed drugs
Register data. Drug outtake according to the drug register held by the Swedish National Board of Health.
Time frame: Baseline
Prescribed drugs
Register data. Drug outtake according to the drug register held by the Swedish National Board of Health.
Time frame: 1 year
Prescribed drugs
Register data. Drug outtake according to the drug register held by the Swedish National Board of Health.
Time frame: 2 year
Prescribed drugs
Register data. Drug outtake according to the drug register held by the Swedish National Board of Health.
Time frame: 3 year
Prescribed drugs
Register data. Drug outtake according to the drug register held by the Swedish National Board of Health.
Time frame: 4 year
Prescribed drugs
Register data. Drug outtake according to the drug register held by the Swedish National Board of Health.
Time frame: 5 year
Started Jan 2019 (actual). Primary completion is estimated for Jan 2027, 96 months after the start.
Of 74 non-industry observational studies under Opioid-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 96 months is above that.
Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.